SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Q3 product rev +89% YoY

Ascendis Pharma A/S · 6-K filed Nov 12, 2026 at 07:45 ET

At the news

BULLISHIMPACT 6/10

6-K filed Nov 12, 2026 at 07:45 ET

Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% YoY), driven by YORVIPATH (EUR 291M, +103% YoY), SKYTROFA (EUR 59M), and YUVIWEL (EUR 16M). The company achieved an operating profit of EUR 125M (34% margin) compared to EUR 11M a year ago, and net profit of EUR 74M (EUR 1.08 diluted EPS) vs a net loss of EUR 61M. The company received positive CHMP and COMP opinions for TransCon CNP in the EU, with a final EC decision expected in Q4 2026.

  • Q3 2026 product revenue EUR 366M, +89% year-over-year from EUR 194M
  • YORVIPATH revenue EUR 291M, +103% YoY from EUR 143M
  • SKYTROFA revenue EUR 59M vs EUR 51M YoY
  • YUVIWEL revenue EUR 16M (launched Q2 2026, no prior-year comparison)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access